X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (748) 748
life sciences & biomedicine (728) 728
humans (638) 638
oncology (485) 485
male (468) 468
middle aged (378) 378
female (375) 375
aged (339) 339
adult (294) 294
cancer (226) 226
chemotherapy (212) 212
treatment outcome (207) 207
refractory (192) 192
care and treatment (185) 185
hematology (174) 174
antineoplastic combined chemotherapy protocols - therapeutic use (169) 169
aged, 80 and over (158) 158
antineoplastic agents - therapeutic use (136) 136
research (130) 130
medicine & public health (127) 127
patients (109) 109
drug resistance, neoplasm (108) 108
pharmacology & pharmacy (104) 104
prognosis (102) 102
disease-free survival (101) 101
analysis (92) 92
clinical trials (91) 91
metastasis (89) 89
retrospective studies (85) 85
drug therapy (84) 84
adolescent (82) 82
antineoplastic combined chemotherapy protocols - adverse effects (82) 82
tumors (80) 80
prostate cancer (78) 78
prostatic neoplasms - drug therapy (74) 74
survival rate (70) 70
young adult (68) 68
recurrence (67) 67
antineoplastic agents (66) 66
antimitotic agents (63) 63
drug administration schedule (62) 62
relapsed (62) 62
disease progression (60) 60
health aspects (60) 60
hematology, oncology and palliative medicine (60) 60
survival analysis (60) 60
antineoplastic agents - adverse effects (59) 59
relapse (58) 58
development and progression (57) 57
cancer therapies (56) 56
lymphomas (56) 56
medical research (56) 56
salvage therapy (56) 56
neoplasm recurrence, local - drug therapy (55) 55
toxicity (55) 55
neoplasm staging (53) 53
pharmacology/toxicology (53) 53
animals (51) 51
multiple myeloma (50) 50
antineoplastic agents - administration & dosage (49) 49
deoxycytidine - analogs & derivatives (49) 49
mutation (49) 49
neoplasms - drug therapy (49) 49
dose-response relationship, drug (48) 48
transplantation (48) 48
urology & nephrology (48) 48
cancer research (47) 47
docetaxel (47) 47
review (47) 47
leukemia (46) 46
prostatic neoplasms - pathology (46) 46
gemcitabine (45) 45
patient outcomes (45) 45
anemia (44) 44
child (44) 44
immunotherapy (44) 44
dosage and administration (43) 43
survival (43) 43
medicine, experimental (42) 42
oncology, experimental (42) 42
risk factors (42) 42
deoxycytidine - administration & dosage (41) 41
lung neoplasms - drug therapy (41) 41
antineoplastic combined chemotherapy protocols - administration & dosage (40) 40
hormone-refractory prostate cancer (40) 40
maximum tolerated dose (40) 40
follow-up studies (39) 39
pediatrics (39) 39
kaplan-meier estimate (38) 38
thyroid cancer (38) 38
internal medicine (37) 37
medical prognosis (37) 37
multiple myeloma - drug therapy (37) 37
neoplasm metastasis (37) 37
diseases (36) 36
adenocarcinoma - drug therapy (35) 35
complications and side effects (35) 35
studies (35) 35
bevacizumab (33) 33
neoplasms. tumors. oncology. including cancer and carcinogens (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (913) 913
Korean (6) 6
Japanese (3) 3
Polish (3) 3
Spanish (3) 3
French (2) 2
German (2) 2
Italian (2) 2
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer treatment reviews, ISSN 0305-7372, 01/2016, Volume 42, pp. 47 - 55
Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase... 
Hematology, Oncology and Palliative Medicine | Refractory | Medullary | Advanced | Multikinase | Survival | Differentiated | Life Sciences & Biomedicine | Oncology | Science & Technology | Thyroid Neoplasms - enzymology | Humans | Receptors, Growth Factor - antagonists & inhibitors | Infant | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Everolimus - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Quinolines - administration & dosage | Quinolines - pharmacology | Thyroid Neoplasms - therapy | Iodine Radioisotopes - therapeutic use | Multicenter Studies as Topic | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Carcinoma - enzymology | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Carcinoma - drug therapy | Carboplatin - administration & dosage | Neoplasms - enzymology | Phenylurea Compounds - therapeutic use | Clinical Trials as Topic | Combined Modality Therapy | Thyroidectomy | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Phenylurea Compounds - administration & dosage | Signal Transduction - drug effects | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Carcinoma - therapy | Mice | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | Quinolines - adverse effects | Development and progression | Thyroid cancer | Tumors
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2013, Volume 31, Issue 1, pp. 77 - 84
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 48, Issue 18, pp. 3319 - 3327
...), maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of SF1126, in patients with advanced solid and B-cell malignancies... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | PI3K/mTORC pathway | SF1126 | Pharmacokinetics | Refractory solid tumours | B-cell malignancies | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Oligopeptides - therapeutic use | Young Adult | Chromones - adverse effects | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Chromones - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Maximum Tolerated Dose | Oligopeptides - administration & dosage | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Oligopeptides - pharmacology | Proteins - antagonists & inhibitors | Prodrugs - administration & dosage | Multiprotein Complexes | Salvage Therapy | Chromones - administration & dosage | Molecular Targeted Therapy | Oligopeptides - adverse effects | Mechanistic Target of Rapamycin Complex 1 | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Hypokalemia - chemically induced | Adult | Female | Antineoplastic Agents - pharmacology | Chromones - therapeutic use | Hematologic Diseases - chemically induced | Oligopeptides - pharmacokinetics | Neoplasms - enzymology | Chromones - pharmacokinetics | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Aged | Prodrugs - therapeutic use | Protein Kinase Inhibitors - pharmacology | Infusions, Intravenous | Prodrugs - pharmacology | Gastrointestinal Diseases - chemically induced | Medicine, Experimental | Medical research | Care and treatment | Emergency medical services | Cancer | Index Medicus | PI3K | mTORC pathway
Journal Article
Journal Article